Answers are grounded in this paper and cite their sources.
BACKGROUND: Risdiplam improves motor function in spinal muscular atrophy (SMA), especially in children. In adults, subtle changes may not be captured by standard motor scales. OBJECTIVE: To describe 24-month motor outcomes, perceived global change, and safety of risdiplam in adults with SMA types 2 and 3 in routine practice. METHODS: In this retrospective two-center study, MFM-32, HFMSE, and RULM were assessed at baseline and after 6, 12, and 24 months, and patient- and clinician-rated Clinical Global Impression (CGI) at 12 and 24 months. RESULTS: All 24 patients (14 [58%] with SMA type 2) completed 24 months of risdiplam treatment. The median (min, max) MFM-32 score increased by 3 (- 2, 11) at 12 months (p < 0.001) and by 3 (- 8, 14) at 24 months (p = 0.004), whereas median HFMSE and RULM changes were 0 at both time points and did not remain significant after Holm correction. At 24 months, a clinically meaningful improvement was observed in 14/24 (58%) patients on the MFM-32, 3/24 (13%) on the HFMSE, and 7/24 (29%) on the RULM; 20/24 (83%) rated themselves as improved compared with baseline on the CGI, mostly minimally. CONCLUSIONS: In this real-world cohort of adults with advanced SMA, 24 months of risdiplam treatment were associated with motor stability and, in more than half of patients, with clinically meaningful improvement, whereas natural history would predict progressive decline. The MFM-32 captured this improvement better than HFMSE and RULM, in line with patients' and clinicians' CGI ratings; larger controlled studies are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Sframeli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: